Syndax Pharmaceuticals reported preliminary, unaudited fourth‑quarter and full‑year 2025 financial results, posting $44 million in Revuforj net revenue and $56 million in Niktimvo net revenue for the quarter, and ending the year with $394 million in cash, cash equivalents and marketable securities.
Revuforj, the company’s first‑in‑class AML therapy, generated $44 million in Q4 revenue, a 38% sequential increase from the $32 million reported in Q3. The drug’s U.S. FDA approval for relapsed or refractory NPM1‑mutant acute myeloid leukemia on October 24, 2025 has accelerated prescription uptake, driving the quarterly growth and contributing to an estimated full‑year net revenue of $125 million.
Niktimvo, launched earlier in 2025, produced $56 million in Q4 revenue. Syndax’s share of the collaboration with Incyte is roughly 25‑30% of Niktimvo’s total net revenue, translating to an estimated $38‑$45 million in earnings for the company. The product’s launch and early market penetration have supported the $152 million total net revenue reported by Incyte for the year, underscoring robust demand for the therapy.
The company’s $394 million cash balance provides a strong runway to fund ongoing clinical development, support commercial expansion of Revuforj and Niktimvo, and move toward profitability. The cash position also cushions the company against potential short‑term market volatility and allows for strategic investments in pipeline candidates.
Chief Executive Officer Michael A. Metzger described the year as “transformational,” noting that Syndax secured three FDA approvals in 14 months and that the commercial launch of Revuforj and Niktimvo has positioned the company as a leading oncology player. Metzger emphasized the company’s transition to a commercial‑stage oncology business and its confidence in achieving profitability as product revenue scales.
The results signal strong demand for Syndax’s oncology portfolio, a solid cash foundation, and a clear path to profitability. Continued growth in Revuforj and Niktimvo, coupled with pipeline progress, positions the company to capture additional market share and generate sustainable long‑term value.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.